IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ALBERICI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.500
AS - Asia 2.534
EU - Europa 1.538
SA - Sud America 737
AF - Africa 70
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 8.398
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.414
SG - Singapore 975
BR - Brasile 632
CN - Cina 549
HK - Hong Kong 438
IT - Italia 344
UA - Ucraina 233
DE - Germania 222
VN - Vietnam 205
GB - Regno Unito 177
RU - Federazione Russa 148
TR - Turchia 137
FI - Finlandia 110
IE - Irlanda 79
PL - Polonia 56
CA - Canada 47
IN - India 46
AR - Argentina 43
BD - Bangladesh 35
FR - Francia 28
MX - Messico 27
NL - Olanda 25
AT - Austria 23
ID - Indonesia 23
JP - Giappone 23
IQ - Iraq 21
ZA - Sudafrica 21
SE - Svezia 17
EC - Ecuador 16
CO - Colombia 15
CZ - Repubblica Ceca 15
DZ - Algeria 14
EG - Egitto 11
PY - Paraguay 11
SA - Arabia Saudita 11
BE - Belgio 10
ES - Italia 10
MA - Marocco 10
EU - Europa 9
LT - Lituania 9
UZ - Uzbekistan 9
PK - Pakistan 8
CL - Cile 7
IR - Iran 7
AU - Australia 6
KZ - Kazakistan 6
AZ - Azerbaigian 5
IL - Israele 5
PE - Perù 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
KE - Kenya 4
KG - Kirghizistan 4
PH - Filippine 4
PT - Portogallo 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CH - Svizzera 3
LB - Libano 3
LV - Lettonia 3
NP - Nepal 3
RO - Romania 3
UY - Uruguay 3
AM - Armenia 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GY - Guiana 2
JM - Giamaica 2
JO - Giordania 2
KR - Corea 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
OM - Oman 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KI - Kiribati 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
NR - Nauru 1
RS - Serbia 1
SD - Sudan 1
SN - Senegal 1
TH - Thailandia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 8.398
Salva come PNG Salva come JPEG
Città #
Hong Kong 437
Fairfield 420
Singapore 391
Ashburn 327
Woodbridge 226
Beijing 204
Houston 186
Jacksonville 176
Seattle 166
Wilmington 154
Cambridge 151
Princeton 145
The Dalles 123
New York 108
Istanbul 97
Los Angeles 89
Helsinki 83
Ho Chi Minh City 79
Dublin 77
Chandler 72
Dallas 71
Ann Arbor 70
São Paulo 59
Munich 53
Warsaw 50
Moscow 48
Hanoi 46
Buffalo 44
Chicago 43
Redondo Beach 40
San Diego 38
Brescia 35
Des Moines 31
Shanghai 30
Nuremberg 29
Milan 25
London 24
Turku 21
Frankfurt am Main 20
Romola 20
Toronto 18
Rio de Janeiro 17
Santa Clara 17
Meram 16
San Francisco 16
Tokyo 16
Florence 14
Montreal 14
Brno 13
Denver 13
Düsseldorf 13
Algiers 12
Brooklyn 12
Chennai 12
Tianjin 12
Belo Horizonte 11
Kocaeli 11
Mexico City 11
Brasília 10
Brussels 10
Changsha 10
Dhaka 10
Jinan 10
Orem 10
Atlanta 9
Boston 9
Campinas 9
Curitiba 9
Quito 9
Vienna 9
Goiânia 8
Lauterbourg 8
Nanjing 8
Phoenix 8
Stockholm 8
Bologna 7
Buenos Aires 7
Haiphong 7
Hortolândia 7
Johannesburg 7
Ninh Bình 7
Shenyang 7
Tashkent 7
Amsterdam 6
Ardabil 6
Augusta 6
Baghdad 6
Cape Town 6
Falkenstein 6
Gonars 6
Guangzhou 6
Joinville 6
Lappeenranta 6
Poplar 6
Portsmouth 6
Rome 6
San Mateo 6
Sorocaba 6
Washington 6
Zhengzhou 6
Totale 5.068
Salva come PNG Salva come JPEG
Nome #
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis 157
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC) 145
Genetics of ANCA-Associated Vasculitis 142
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection 136
Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN 133
SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response 115
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 113
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 111
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 110
Pneumocystis Jirevocii and SARS-CoV-2 co-infection: A common feature in transplant recipients? 110
A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis 108
Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy 108
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 107
A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia 106
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 105
Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience 105
Nonlupus Full House Nephropathy 101
Impact of rituximab trials on the treatment of ANCA-associated vasculitis 99
Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features 97
Update on ANCA-associated vasculitis: from biomarkers to therapy 97
Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series 96
Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial 95
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: A systemic large vessel vasculitis? 95
PTPN22 R620W polymorphism in the ANCA-associated vasculitides 95
[Glomerulonefriti da tossici e farmaci] 95
Lupus nephritis and B-cell targeting therapy 94
Measurement of damage in systemic vasculitis: A comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index 94
[Infection-related glomerulonephritis: the new face of an old disease] 94
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC) 93
Orofacial granulomatosis treated with low-level laser therapy: A case report 92
The role of analytical methods for the determination of trace elements in environmental biomonitors 91
IgG4 immune response in Churg-Strauss syndrome 91
Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis 91
Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis 90
Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease 90
Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation 89
Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis 89
Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: are anti-platelets the answer? 88
Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-α in patients with renal cell carcinoma 88
Peripheral inflammatory arthritis in patients with chronic periaortitis: Report of five cases and review of the literature 87
[The complex etiopathogenesis of focal segmental glomerulosclerosis] 87
[Peritoneal dialysis: what have we learned from the Covid-19 pandemic?] 87
FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome 86
[Managing patients in dialysis and with kidney transplant infected with Covid-19] 84
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients 83
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 83
Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis 79
Chronic periaortitis associated with membranous nephropathy: Clues to common pathogenetic mechanisms 77
Avacopan for the treatment of ANCA-associated vasculitis 77
[ADPKD and intracranial aneurysms: indications for screening, follow-up and clinical management] 77
Impact of COVID-19 vaccines in patients on hemodialysis: an Italian multicentre cohort study 76
Genetics of ANCA-associated vasculitides: HLA and beyond 75
Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease–spectrum phenotype 74
The Authors Reply 74
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. 74
An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving 73
FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis 72
Hemodialysis techniques and outcomes in patients with COVID-19: The Brescia experience 71
Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry 71
Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination 69
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 69
The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult 68
Association of a polymorphism of the Fc gamma-receptor 2A (FCGR2A) gene with chronic periaortitis 68
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) 68
Lessons From the Clinic: ADPKD Genetic Test Unraveling Severe Phenotype, Intrafamilial Variability, and New, Rare Causing Genotype 68
Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD 65
[State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy] 65
Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort' 64
[Anti-SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases. Recommendations of the Italian Society on Nephrology's Working Group on Renal Immunopathology (Vaccine Task Force)] 62
Variable Expressivity of HNF1B Nephropathy From Renal Cysts and Diabetes to Medullary Sponge Kidney Through Tubulo-interstitial Kidney Disease 61
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab 60
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial 59
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies 59
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? 59
Editorial: “Toward Precision Medicine in Vasculitis” 59
Sustained post-rituximab B cell depletion is common in ANCA-associated Vasculitis and affected by sex and renal function 56
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study 53
Peritoneal dialysis discontinuation: to the root of the problem 52
Rituximab in Membranous Nephropathy 52
Clinical Significance of the Cystic Phenotype in Alport Syndrome 52
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy 52
Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey 51
Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia 51
Feasibility of MALDI-MSI-Based Proteomics Using Bouin-Fixed Pathology Samples: Untapping the Goldmine of Nephropathology Archives 50
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial 49
Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy 48
The ideal marker for measuring GFR: what are we looking for? 48
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 48
Congo Red Staining in Digital Pathology: The Streamlined Pipeline for Amyloid Detection Through Congo Red Fluorescence Digital Analysis 47
Treatment goals in ANCA-associated vasculitis: defining success in a new era 47
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome 47
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 47
Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study 45
Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementation 43
The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study 43
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial 42
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial 41
COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases 40
Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan 39
Spatial resolution of renal amyloid deposits through MALDI-MSI: a combined digital and molecular approach to monoclonal gammopathies 39
Totale 7.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.457
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.457
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021826 0 0 0 0 0 185 35 134 83 165 114 110
2021/2022600 44 104 22 18 2 64 28 36 37 58 37 150
2022/2023373 83 2 7 7 20 114 0 30 48 2 28 32
2023/2024811 32 30 29 63 53 111 28 34 236 11 26 158
2024/20251.998 8 26 42 236 150 153 199 85 209 277 397 216
2025/20262.551 338 603 412 743 387 68 0 0 0 0 0 0
Totale 8.527